Invacare Corporation, together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide. The company operates through four segments: North America/Home Medical Equipment, Institutional Products Group, Europe, and the Asia/Pacific. It offers mobility and seating products, such as power wheelchairs under the Invacare TDX brand; custom manual wheelchairs under the Invacare, Invacare Top End, and Küschall brand names; and seating and positioning products. The company also provides lifestyle products, including pressure relieving overlays and mattress replacement systems under the Invacare Softform and microAIR brands; safe resident handling products; residential care and home beds and bed accessories, and manual wheelchairs under the Invacare brand name; and personal care products. In addition, the company offers respiratory therapy products comprising stationary oxygen concentrators under the Perfecto2, Perfecto2 V, and Platinum brands; Invacare HomeFill oxygen systems; and Invacare SOLO2 and XPO2 transportable oxygen concentrators. Further, it sells and distributes healthcare furnishings consisting of long-term care beds, case goods, safe patient handling equipment, and other equipment and accessories for long-term care customers. It sells its products primarily to home medical equipment providers through retail and e-commerce channels, as well as to residential care operators, distributors, and government health service customers through its sales force, independent manufacturers' representatives, and distributors. Invacare Corporation was founded in 1885 and is headquartered in Elyria, Ohio.
Industry, Sector and Symbol
Industry Surgical appliances & supplies
Sub-IndustryHealth Care Equipment
SectorMedical
Phone440-329-6000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$972.35 million
Profitability
Miscellaneous
Employees4,200
OptionableOptionable
Invacare (NYSE:IVC) Frequently Asked Questions
What is Invacare's stock symbol?
Invacare trades on the New York Stock Exchange (NYSE) under the ticker symbol "IVC."
How often does Invacare pay dividends? What is the dividend yield for Invacare?
Invacare declared a quarterly dividend on Thursday, November 29th. Stockholders of record on Friday, January 4th will be paid a dividend of $0.0125 per share on Thursday, January 17th. This represents a $0.05 dividend on an annualized basis and a dividend yield of 0.52%. The ex-dividend date of this dividend is Thursday, January 3rd. View Invacare's Dividend History.
How were Invacare's earnings last quarter?
Invacare Co. (NYSE:IVC) posted its quarterly earnings data on Wednesday, February, 13th. The health services provider reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.42) by $0.26. The health services provider had revenue of $244.60 million for the quarter, compared to the consensus estimate of $239.22 million. Invacare had a negative net margin of 4.52% and a negative return on equity of 11.14%. The company's quarterly revenue was down 2.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) earnings per share. View Invacare's Earnings History.
When is Invacare's next earnings date?
What price target have analysts set for IVC?
3 Wall Street analysts have issued 12 month price targets for Invacare's stock. Their predictions range from $15.00 to $23.00. On average, they expect Invacare's share price to reach $19.00 in the next year. This suggests a possible upside of 96.9% from the stock's current price. View Analyst Price Targets for Invacare.
What is the consensus analysts' recommendation for Invacare?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invacare in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Invacare.
What are Wall Street analysts saying about Invacare stock?
Here are some recent quotes from research analysts about Invacare stock:
- 1. Needham & Company LLC analysts commented, "IVC’s 4Q18 revenue and EPS beat consensus. In 4Q18, IVC’s segment growth improved except for NA/HME, which slowed. Free cash flow also improved in 4Q18 and IVC achieved positive EBITDA. IVC updated its longer-term EBITDA guidance and now expects to reach a run rate of $85-105M by the end of 2020 (vs. prior guidance of $100M by 3Q20). And while the 4Q18 results were encouraging, we believe more details on IVC’s updated Transformation Plan will be just as important. Given the improvements in 4Q18 and potential for more aggressive restructuring, we reiterate our Buy rating." (2/14/2019)
- 2. According to Zacks Investment Research, "Invacare Corporation is a leading manufacturer and distributor in its markets for medical equipment used in non-acute care settings. At its core, the company designs, manufactures and distributes medical devices that help people to move, breathe, rest and perform essential hygiene. The company provides clinically complex medical device solutions for congenital (e.g., cerebral palsy, muscular dystrophy, spina bifida), acquired (e.g., stroke, spinal cord injury, traumatic brain injury, post-acute recovery, pressure ulcers) and degenerative (e.g., ALS, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly, bariatric) ailments. The company's products are important parts of care for people with a wide range of challenges, from those who are active and involved in work or school each day and may need additional mobility or respiratory support, to those who are cared for in residential care settings, at home and in rehabilitation centers. " (1/9/2019)
Has Invacare been receiving favorable news coverage?
Headlines about IVC stock have trended positive this week, according to InfoTrie. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Invacare earned a media sentiment score of 2.4 on InfoTrie's scale. They also gave news articles about the health services provider a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Invacare's key competitors?
Some companies that are related to Invacare include Establishment Labs (ESTA), Sientra (SIEN), RTI Surgical (RTIX), Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), NanoVibronix (NAOV), Wound Management Technologies (WNDM), Precision Therapeutics (AIPT), Bionik Laboratories (BNKL), Rewalk Robotics (RWLK), Histogenics (HSGX), Allied Healthcare Products (AHPI), Avitar (AVTI) and Halyard Health (HYH).
Who are Invacare's key executives?
Invacare's management team includes the folowing people:
- Mr. Matthew E. Monaghan, Chairman, Pres & CEO (Age 51)
- Ms. Kathleen P. Leneghan, Sr. VP & CFO (Age 56)
- Mr. Anthony C. LaPlaca, Sr. VP, Gen. Counsel & Sec. (Age 61)
- Mr. Ralf Ledda, Sr. VP & GM of EMEA (Age 51)
- Lois Lee, Director of Treasury and Investor Relations
Who are Invacare's major shareholders?
Invacare's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.22%), Elk Creek Partners LLC (9.35%), Dimensional Fund Advisors LP (8.20%), Royce & Associates LP (6.70%), Krensavage Asset Management LLC (4.01%) and Krensavage Asset Management LLC (4.01%). Company insiders that own Invacare stock include Anthony Laplaca, Baiju R Shah, C Martin Harris, Clifford D Nastas, Dale C Laporte, Dean J Childers, Kathleen P Leneghan and Matthew E Monaghan. View Institutional Ownership Trends for Invacare.
Which institutional investors are selling Invacare stock?
IVC stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Monarch Partners Asset Management LLC, Millennium Management LLC, Dimensional Fund Advisors LP, Barclays PLC, United Services Automobile Association, Northern Trust Corp and Eversept Partners LP. Company insiders that have sold Invacare company stock in the last year include Anthony Laplaca, Baiju R Shah, C Martin Harris and Dean J Childers. View Insider Buying and Selling for Invacare.
Which institutional investors are buying Invacare stock?
IVC stock was purchased by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Royce & Associates LP, Circle Road Advisors LP, Two Sigma Investments LP, Krensavage Asset Management LLC, Krensavage Asset Management LLC, Alambic Investment Management L.P. and Prospect Capital Advisors LLC. Company insiders that have bought Invacare stock in the last two years include Clifford D Nastas, Kathleen P Leneghan and Matthew E Monaghan. View Insider Buying and Selling for Invacare.
How do I buy shares of Invacare?
Shares of IVC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invacare's stock price today?
One share of IVC stock can currently be purchased for approximately $9.65.
How big of a company is Invacare?
Invacare has a market capitalization of $320.38 million and generates $972.35 million in revenue each year. The health services provider earns $-76,540,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. Invacare employs 4,200 workers across the globe.
What is Invacare's official website?
How can I contact Invacare?
Invacare's mailing address is ONE INVACARE WAY, ELYRIA OH, 44035. The health services provider can be reached via phone at 440-329-6000 or via email at [email protected]
MarketBeat Community Rating for Invacare (NYSE IVC)
MarketBeat's community ratings are surveys of what our community members think about Invacare and other stocks. Vote "Outperform" if you believe IVC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IVC will underperform the S&P 500 over the long term. You may vote once every thirty days.
